Business Description
AnaptysBio Inc
NAICS : 325412
SIC : 2834
ISIN : US0327241065
Total Employee Number:
104Description
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 21.04 | |||||
Equity-to-Asset | 0.04 | |||||
Debt-to-Equity | 1.07 | |||||
Debt-to-EBITDA | 0.23 | |||||
Interest Coverage | 0.49 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.31 | |||||
Beneish M-Score | -2.72 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 181.7 | |||||
3-Year EPS without NRI Growth Rate | 53.5 | |||||
3-Year Book Growth Rate | -47.5 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 94.74 | |||||
14-Day RSI | 99.97 | |||||
12-1 Month Momentum % | 15.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.58 | |||||
Quick Ratio | 7.58 | |||||
Cash Ratio | 6.87 | |||||
Days Sales Outstanding | 54.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.6 | |||||
Shareholder Yield % | 2.03 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | 17.56 | |||||
Net Margin % | -11.53 | |||||
EBITDA Margin % | 25.17 | |||||
FCF Margin % | 0.9 | |||||
OCF Margin % | 0.93 | |||||
ROE % | -1362.65 | |||||
ROA % | -7.42 | |||||
ROIC % | 82.57 | |||||
3-Year ROIIC % | -114.12 | |||||
ROC (Joel Greenblatt) % | 233.3 | |||||
ROCE % | 17.45 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 7.74 | |||||
PB Ratio | 144.46 | |||||
Price-to-Tangible-Book | 144.09 | |||||
Price-to-Free-Cash-Flow | 224.1 | |||||
Price-to-Operating-Cash-Flow | 222.53 | |||||
EV-to-EBIT | 28.63 | |||||
EV-to-EBITDA | 27.44 | |||||
EV-to-Revenue | 6.91 | |||||
EV-to-Forward-Revenue | 6.66 | |||||
EV-to-FCF | 364.01 | |||||
Price-to-GF-Value | 1.04 | |||||
Earnings Yield (Greenblatt) % | 3.49 | |||||
FCF Yield % | 0.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AnaptysBio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 4,244.035 | ||
| EPS (TTM) (MXN) | -20.023 | ||
| Beta | 0.0173 | ||
| 3-Year Sharpe Ratio | -0.5 | ||
| 3-Year Sortino Ratio | -1.62 | ||
| Volatility % | 15.17 | ||
| 14-Day RSI | 99.97 | ||
| 14-Day ATR (MXN) | 0.000014 | ||
| 20-Day SMA (MXN) | 445.25081 | ||
| 12-1 Month Momentum % | 15.17 | ||
| 52-Week Range (MXN) | 386.595017 - 445.250813 | ||
| Shares Outstanding (Mil) | 29.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AnaptysBio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AnaptysBio Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-04 | In 124 days | ||
| General meeting for 2026 | 2026-08-11 09:00 | In 40 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 34 days | ||
| First quarter earnings results for 2026 | 2026-05-12 | 445.25 (+0.00%) | ||
| H.C. Wainwright 2nd Annual Royalty Company Virtual Conference | 2026-05-06 13:30 | 445.25 (+0.00%) | ||
| Leerink Global Healthcare Conference | 2026-03-11 14:20 | 445.25 (+0.00%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-10 08:30 | 445.25 (+0.00%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-04 11:50 | 445.25 (+0.00%) | ||
| Annual report for 2025 | 2026-03-03 | 445.25 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-03 | 445.25 (+0.00%) |
Show
Entries
AnaptysBio Inc Frequently Asked Questions
What is AnaptysBio Inc(MEX:ANAB)'s stock price today?
The current price of MEX:ANAB is MXN445.25. The 52 week high of MEX:ANAB is MXN445.25 and 52 week low is MXN386.60.
When is next earnings date of AnaptysBio Inc(MEX:ANAB)?
The next earnings date of AnaptysBio Inc(MEX:ANAB) is 2026-08-06 Est..
Does AnaptysBio Inc(MEX:ANAB) pay dividends? If so, how much?
AnaptysBio Inc(MEX:ANAB) does not pay dividend.
Press Release
Articles on AnaptysBio Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers